Seven biotechs led the way.
News & Analysis: ArQule
This cancer-drug developer received a buyout offer from a big pharmaceutical company.
Helping people stricken with illness can be richly rewarding in more ways than one.
Two big deals for cancer drug companies made news today. Merck plans to buy ArQule and Sanofi will pay up to buy Synthorx.
A $2.7 billion buyout offer is causing this biotech stock to take off.
These companies have some important presentations scheduled for the last big oncology conference of the year.
Here's how they could keep on rocketing higher.
An update from an ongoing clinical trial appears to have disappointed investors, but that's not actually warranted by the data.
ARQL earnings call for the period ending September 30, 2019.
The pharma company has wowed investors with solid clinical data multiple times this year.